Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Rana Maroun, Laetitia Fleury, Gaelle Nachbaur, Franck Maunoury, Jean-louis Vanhille & Isabelle Durand-Zaleski. (2017) Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database. Current Medical Research and Opinion 33:10, pages 1755-1762.
Read now
Read now
Vivek Narayan & Naomi Balzer Haas. (2016) Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. International Journal of Nephrology and Renovascular Disease 9, pages 65-72.
Read now
Read now
Articles from other publishers (31)
Alvydas Cesas, Vincas Urbonas, Skaiste Tulyte, Rasa Janciauskiene, Sigita Liutkauskiene, Ingrida Grabauskyte & Ignas Gaidamavicius. (2023) Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective–prospective cohort multicentre study. Journal of Cancer Research and Clinical Oncology 149:10, pages 6979-6988.
Crossref
Crossref
Blánaid M. Hicks, Danielle S. Chun, Sharon Peacock Hinton, Christine D. Hsu, Hung-Jui Tan & Jennifer L. Lund. (2022) Patterns of first-line targeted therapy utilization and adherence among older adults diagnosed with metastatic renal cell carcinoma. Journal of Geriatric Oncology 13:3, pages 325-333.
Crossref
Crossref
Brian A. Costello, Nrupen A. Bhavsar, Yousef Zakharia, Sumanta K. Pal, Ulka Vaishampayan, Heather Jim, Mayer N. Fishman, Ana M. Molina, Christos E. Kyriakopoulos, Che-Kai Tsao, Leonard J. Appleman, Benjamin A. Gartrell, Arif Hussain, Walter M. Stadler, Neeraj Agarwal, Russell K. Pachynski, Thomas E. Hutson, Hans J. Hammers, Christopher W. Ryan, Jack Mardekian, Azah Borham, Daniel J. George & Michael R. Harrison. (2022) A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clinical Genitourinary Cancer 20:1, pages 1-10.
Crossref
Crossref
Nazli Dizman, Zeynep E. Arslan, Matthew Feng & Sumanta K. Pal. (2020) Sequencing Therapies for Metastatic Renal Cell Carcinoma. Urologic Clinics of North America 47:3, pages 305-318.
Crossref
Crossref
Sumanta Pal, Jun Gong, Shivani K. Mhatre, Shih-Wen Lin, Andy Surinach, Sarika Ogale, Rini Vohra, Herschel Wallen & Daniel George. (2019) Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer 19:1.
Crossref
Crossref
Sreeram V Ramagopalan, Bill Malcolm, Evie Merinopoulou, Laura McDonald & Andrew Cox. (2019) Automated extraction of treatment patterns from social media posts: an exploratory analysis in renal cell carcinoma. Future Oncology 15:31, pages 3587-3596.
Crossref
Crossref
Julia F. SlejkoJuan-David RuedaJames A. TrovatoEmily F. GormanGail BetzStephen ArconaChristopher ZackerBruce Stuart. (2019) A Comprehensive Review of Methods to Measure Oral Oncolytic Dose Intensity Using Retrospective Data. Journal of Managed Care & Specialty Pharmacy 25:10, pages 1125-1132.
Crossref
Crossref
Thiago Ferreira de Souza, Thiago Quinaglia, Tomas G. Neilan & Otávio R. Coelho-Filho. (2019) Assessment of Cardiotoxicity of Cancer Chemotherapy. Magnetic Resonance Imaging Clinics of North America 27:3, pages 533-544.
Crossref
Crossref
Kenichi Harada, Masahiro Nozawa, Motohide Uemura, Katsunori Tatsugami, Takahiro Osawa, Kazutoshi Yamana, Go Kimura, Masato Fujisawa, Norio Nonomura, Masatoshi Eto, Nobuo Shinohara, Yoshihiko Tomita, Yukihiro Kondo, Kenya Ochi, Yoshio Anazawa & Hirotsugu Uemura. (2018) Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan. International Journal of Urology 26:2, pages 202-210.
Crossref
Crossref
Rana Maroun, Laura Mitrofan, Laure Benjamin, Gaelle Nachbaur, Franck Maunoury, Philippe Le Jeunne & Isabelle Durand-Zaleski. (2018) Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data. BMC Cancer 18:1.
Crossref
Crossref
Caroline Roelants, Sofia Giacosa, Catherine Pillet, Rémi Bussat, Pierre Champelovier, Olivier Bastien, Laurent Guyon, Valentin Arnoux, Claude Cochet & Odile Filhol. (2018) Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma. Oncotarget 9:53, pages 30066-30078.
Crossref
Crossref
Elyse SwallowAndrew MessaliSameer GhateEvangeline McDonaldEmilie DuchesneauJose Ricardo Perez. (2018) The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma. Journal of Managed Care & Specialty Pharmacy 24:4, pages 335-343.
Crossref
Crossref
Tendo Satoh, Takuya Koie, Hirotaka Horiguchi, Noriko Tokui, Satoshi Narita & Chikara Ohyama. (2017) Longer recurrence-free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus. Clinical Case Reports 5:12, pages 1950-1953.
Crossref
Crossref
Chenkui Miao, Chao Liang, Ye Tian, Aiming Xu, Jundong Zhu, Kai Zhao, Jianzhong Zhang, Yibo Hua, Shouyong Liu, Huiyu Dong, Chao Zhang, Shifeng Su, Pu Li, Chao Qin & Zengjun Wang. (2017) Overexpression of CAPN2 promotes cell metastasis and proliferation via AKT/mTOR signaling in renal cell carcinoma. Oncotarget 8:58, pages 97811-97821.
Crossref
Crossref
Sumanta K. Pal, Sameer R. Ghate, Nanxin Li, Elyse Swallow, Miranda Peeples, Miriam L. Zichlin, Jose Ricardo Perez, Neeraj Agarwal & Nicholas J. Vogelzang. (2017) Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER–Medicare Database Analysis. Clinical Genitourinary Cancer 15:4, pages e573-e582.
Crossref
Crossref
Vivek Narayan, Stephen Keefe, Naomi Haas, Le Wang, Igor Puzanov, Mary Putt, Anna Catino, James Fang, Neeraj Agarwal, David Hyman, Amanda M. Smith, Brian S. Finkelman, Hari K. Narayan, Steven Ewer, Chantal ElAmm, Daniel Lenihan & Bonnie Ky. (2017) Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research 23:14, pages 3601-3609.
Crossref
Crossref
Guillermo De Velasco, Wanling Xie, Frede Donskov, Laurence Albiges, Benoit Beuselinck, Sandy Srinivas, Neeraj Agarwal, Jae Lyun Lee, James Brugarolas, Lori A. Wood, Sun-young Rha, Christian Kollmannsberger, Scott North, Ravindran Kanesvaran, Brian I. Rini, Reuben Broom, Haru Yamamoto, Marina D. Kaymakcalan, Daniel Y.C. Heng & Toni K. Choueiri. (2017) Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 15:3, pages 403-410.e2.
Crossref
Crossref
Sumanta K Pal, James E Signorovitch, Nanxin Li, Miriam L Zichlin, Zhimei Liu, Sameer R Ghate, Jose Ricardo Perez & Nicholas J Vogelzang. (2017) Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA. International Journal of Urology 24:4, pages 272-278.
Crossref
Crossref
Yibo Hua, Chao Liang, Jundong Zhu, Chenkui Miao, Yajie Yu, Aimin Xu, Jianzhong Zhang, Pu Li, Shuang Li, Meiling Bao, Jie Yang, Chao Qin & Zengjun Wang. (2017) Expression of lactate dehydrogenase C correlates with poor prognosis in renal cell carcinoma. Tumor Biology 39:3, pages 101042831769596.
Crossref
Crossref
J. Connor Wells, Igor Stukalin, Craig Norton, Sandy Srinivas, Jae Lyun Lee, Frede Donskov, Georg A. Bjarnason, Haru Yamamoto, Benoit Beuselinck, Brian I. Rini, Jennifer J. Knox, Neeraj Agarwal, D. Scott Ernst, Sumanta K. Pal, Lori A. Wood, Aristotelis Bamias, Ajjai S. Alva, Ravindran Kanesvaran, Toni K. Choueiri & Daniel Y.C. Heng. (2017) Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology 71:2, pages 204-209.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
395
414
.
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
199
219
.
Julio Lambea, Urbano Anido, Olatz Etxániz, Luis Flores, Álvaro Montesa, Juan Manuel Sepúlveda & Emilio Esteban. (2016) The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma. Current Oncology Reports 18:11.
Crossref
Crossref
Sabrina C. Cecere, Sabrina Rossetti, Carla Cavaliere, Chiara Della Pepa, Marilena Di Napoli, Anna Crispo, Gelsomina Iovane, Raffaele Piscitelli, Domenico Sorrentino, Gennaro Ciliberto, Piera Maiolino, Paolo Muto, Sisto Perdonà, Massimiliano Berretta, Sandro Pignata, Gaetano Facchini & Carmine D'Aniello. (2016) Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”. Frontiers in Pharmacology 7.
Crossref
Crossref
Elizabeth MacLean, Laura Cisar, Kimberly Mehle, Daria Eremina & Jane M. Quigley. (2016) Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets. Journal of Managed Care & Specialty Pharmacy 22:6, pages 723-732u.
Crossref
Crossref
Sumanta K. Pal, James E. Signorovitch, William M. Reichmann, Nanxin Li, Valerie Koo, Zhimei Liu, Jose Ricardo Perez & Nicholas J. Vogelzang. (2016) Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews. Clinical Genitourinary Cancer 14:2, pages 160-167.e3.
Crossref
Crossref
Dong-Hoe Koo, Inkeun Park, Jin-Hee Ahn, Dae-Ho Lee, Dalsan You, In-Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn & Jae-Lyun Lee. (2015) Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology 77:2, pages 339-347.
Crossref
Crossref
Taiyo Otoshi, Tomoaki Tanaka, Kazuya Morimoto & Tatsuya Nakatani. (2015) Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells. PLOS ONE 10:12, pages e0145769.
Crossref
Crossref
Ana-Iris Schiefer, Ildiko Mesteri, Anna S Berghoff, Andrea Haitel, Manuela Schmidinger, Matthias Preusser & Peter Birner. (2015) Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor. Histopathology 67:6, pages 799-805.
Crossref
Crossref
S. E. K. Fink, S. Pahernik, P. Hallscheidt & M. Zeier. (2015) NierenzellkarzinomRenal cell carcinoma. Der Nephrologe 10:6, pages 513-522.
Crossref
Crossref
Rashmi R. Shah & Joel Morganroth. (2015) Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit. Drug Safety 38:8, pages 693-710.
Crossref
Crossref